Avaxia is an early-stage biotechnology company focused on developing recombinant, gut-targeted antibody therapeutics for gastrointestinal diseases. These unique antibody therapeutics, called Avaximabs™, are orally administered, minimally absorbed drugs that act locally in the gastrointestinal (GI) tract. Avaxia believes that treatment of GI diseases with gut-targeted antibodies has the potential to address important limitations of existing therapies.
Our lead product is a recombinant anti-TNF gut-targeted antibody therapeutic for inflammatory bowel disease (IBD). Avaximab™-TNF binds to and neutralizes TNF, a major driver of inflammation throughout the body. Marketed anti-TNF drugs, such as Remicade® (infliximab), have proven to be effective for the treatment of IBD, including ulcerative colitis and Crohn’s disease. However, these anti-TNF drugs have rare but serious side effects, such as risk of serious infection, because they dampen the immune system throughout the body. Moreover, despite encouraging signs of efficacy in ~40% of patients with moderate to severe disease, many of these patients develop resistance to the systemically administered anti-TNF products after only 1 year of treatment. Avaxia’s Avaximab™-TNF is intended to act locally in the intestines where the disease occurs, potentially treating IBD without some of the significant limitations of currently available products.